Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Enhancing glioblastoma radiotherapy by COMT inhibition

ABSTRACT: Enhancing glioblastoma radiotherapy by COMT inhibition

PROVIDER: PRJNA993639 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25238444_1.fastq.gz	Fastqsanger.gz
	SRR25238444_2.fastq.gz	Fastqsanger.gz
	SRR25238445_1.fastq.gz	Fastqsanger.gz
	SRR25238445_2.fastq.gz	Fastqsanger.gz
	SRR25238446_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Enhancing glioblastoma radiotherapy by COMT inhibition

Project description:Next-generation sequencing (NGS)-derived transcriptomic profiling was carried out to compare the transcriptomic changes mediated by COMT knockout in U87 cells. We found significant enrichment of gene signatures involving IFNa/b signaling in COMT-KO U87 cells compared to control cells. Our analysis also demonstrated that COMT deficiency interferes with mitochondrial functions and induces the expression of genes associated with the anti-viral RNA sensing pathway.

2023-10-12 | GSE237053 | GEO

Combined anti-C1-INH and Radiotherapy against Glioblastoma

Project description:Animals with intracranial glioblastoma of the NS1 cells line were treated with anti-C1-INH +/- radiotherapy or were untreated control animals.

2022-10-19 | E-MTAB-12296 | biostudies-arrayexpress

Transcription profiling of human glioblastoma samples from a homogenous cohort of patients treated within clinical trial with eitehr radiotherapy or radiotherapy and temonzolomide

Project description:Analysis of 80 glioblastoma specimen of patients treated within clinical trials and 4 samples of "normal" brain tissue (non-tumoral). The data was used to identify factors of resistance to a chemoradiation therapy protocol of radiotherapy and concomitant and adjuvant temozolomide (alkylating agent). Experiment Overall Design: 80 glioblastoma specimen and 4 non-tumoral brain samples

2008-10-18 | E-GEOD-7696 | biostudies-arrayexpress

Combined anti-C1-INH and Radiotherapy against Glioblastoma

Project description:Combined anti-C1-INH and Radiotherapy against Glioblastoma

| PRJEB56861 | ENA

The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma

Project description:Glioblastoma is the most common malignant primary brain tumor. Clinically relevant biomarkers are restricted to isocitrate dehydrogenase (IDH) gene 1 or 2 mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Long non-coding RNA (lncRNA) alterations may contribute to glioblastoma pathogenesis and potentially serve as novel biomarkers. The clinical significance of HOXA Transcript Antisense RNA, Myeloid-Specific 1 (HOTAIRM1) was analyzed in multiple glioblastoma gene expression data sets for associations with prognosis and IDH mutation and MGMT promoter methylation status. The role of HOTAIRM1 in glioblastoma biology and radiotherapy resistance was characterized in vitro and in vivo. We identified HOTAIRM1 as a candidate lncRNA whose up-regulation is significantly associated with shorter survival of glioblastoma patients independent from IDH mutation and MGMT promoter methylation. Glioblastoma cell line models uniformly showed reduced cell viability, less invasive growth and diminished colony formation capacity upon HOTAIRM1 down-regulation. Integrated proteogenomic analyses and determination of reactive oxygen species (ROS) levels revealed impaired mitochondrial function and increased ROS levels upon HOTAIRM1 knock-down. HOTAIRM1 knock-down decreased expression of transglutaminase 2 (TGM2) as a candidate protein implicated in mitochondrial function, and knock-down of TGM2 mimicked the phenotype of HOTAIRM1 down-regulation in glioblastoma cells. Moreover, HOTAIRM1 modulates radiosensitivity of glioblastoma cells in vitro and in vivo. Our data support a role for HOTAIRM1 as a driver of biological aggressiveness, radioresistance and poor outcome in glioblastoma. Targeting HOTAIRM1 may be a promising new therapeutic approach.

2022-01-19 | PXD020141 | Pride

Inhibition of lysine-specific demethylase 1 inhibition in glioblastoma

Project description:Inhibition of lysine-specific demethylase 1 inhibition in glioblastoma

| PRJNA929532 | ENA

Rapid PTEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy [ATAC-Seq]

Project description:This study examines the reorganization of transcriptionally active chromatin that underlies the adaptive response of glioblastoma cells to radiotherapy.

2023-12-01 | GSE211148 | GEO

Rapid PTEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy [ChIP-Seq]

Project description:This study examines the reorganization of transcriptionally active chromatin that underlies the adaptive response of glioblastoma cells to radiotherapy.

2023-12-01 | GSE211147 | GEO

The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma

2020-06-10 | GSE152147 | GEO

YTHDF2 inhibition potentiates radiotherapy by reprogramming suppressive myeloid cells

Project description:YTHDF2 inhibition potentiates radiotherapy by reprogramming suppressive myeloid cells

| PRJNA850417 | ENA